摘要
目的回顾性分析以青黄散胶囊为主治疗骨髓增生异常综合征患者的临床疗效。方法纳入骨髓增生异常综合征患者150例,其服用青黄散胶囊至少24个月(每日0.3 g,晚饭后服用),同时联合雄激素和补肾健脾中药汤剂口服。观察患者治疗3、6、9、16、24、30、40个月的外周血血红蛋白(HGB)、血小板计数(PLT)、中性粒细胞计数(ANC),评价各指标获得血液学进步的例数及时间,并对不同危险度、骨髓增生程度患者各指标获得血液学进步时间进行比较;记录治疗40个月患者贫血改善情况和红细胞输注情况。结果 150例患者完成了24个月治疗,其中完成了30个月治疗者136例,完成了40个月治疗者118例。150例患者治疗前HGB、PLT、ANC低于正常的例数分别为115例、129例、56例。治疗40个月期间HGB异常患者较PLT及ANC异常患者血液学进步率高,血液学进步时间短(P<0.05),而PLT与ANC异常患者比较差异无统计学意义(P>0.05)。不同危险度患者各指标获得血液学进步时间差异无统计学意义(P>0.05)。低增生性患者PLT获得血液学进步时间明显长于非低增生性患者(P<0.05)。经Person相关性检验,随着治疗时间延长红细胞输注依赖的患者显著减少(r=-0.92,P<0.05)。结论青黄散胶囊为主治疗骨髓增生异常综合征可明显改善患者外周血HGB、PLT、ANC,且对HGB的改善更为明显,起效时间短,作用时间长。
Objective To retrospectively analyze clinical curative effect of Qinghuang Powder Capsule as the main method in treating patients with myelodysplastic syndrome. dysplastie syndrome were collected. All patients have used Qingh Methods One hundred and fifty cases of myelo- uang Powder Capsule for at least 24 months （0. 3 g daily, taken after dinner）, at the same time combining with orally taking androgen and decoction for tonifying kidney and spleen. Peripheral blood hemoglobin （HGB）, platelet count （PLT）, and neutrophil count （ANC） of patients af- ter being treated for 3, 6, 9, 16, 24, 30 and 40 months were observed. The case number and time of each index ac- quiring hematology progress were evaluated. The time it took for each index of patients with different risk factors and bone marrow hyperplasia degree to acquire hematology progress were compared; and the improvement of anemia and erythrocyte infusion condition in the 40th month of treatment was recorded. Results There were 150 patients who completed the 24-month treatment, of which 136 completing 30-month treatment, and 118 completing 40-month treat- ment. In 150 cases, the number of patients whose HGB, PLT and ANC before treatment lower than normal was 115, 129 and 56 cases respectively. During 40-month treatment, hematology progress rate of patients with abnormal HGB were higher and hematology progress time was shorter than those with abnormal PLT and ANC （P 〈 0. 05 ）, while the difference between patients with abnormal PLT and ANC was not statistically significant （ P 〉 0.05 ）. There was no significant difference in time took for each index improvementbetween patients with different risk to acquire hematolog- ical progress （ P 〉 0. 05 ）. The time took for PLT improvement of patients with low proliferative to acquire hematologi- cal progress was significantly longer than that of non-hypoproliferative patients （ P 〈 0. 05）. Through Person correla- tion test, the patients with erythrocyte infusion dependence were significantly reduced as treatment time stretched （ r = - 0. 92, P 〈 0.05 ）. Conclusion Qinghuang Powder Capsule as the main method treating myelodysplastic syn- drome could obviously improve HGB, PLT, ANC in peripheral blood, and improved HGB more significantly. Its onset time was short and could work for a long time.
出处
《中医杂志》
CSCD
北大核心
2018年第4期303-306,共4页
Journal of Traditional Chinese Medicine
基金
国家自然科学基金(81273931
81673821)
"十三五"第一批重点领域科研项目(ZZ10-016)
北京市科技计划(Z141100006014003)
关键词
骨髓增生异常综合征
髓毒劳
青黄散
血液学进步
myelodysplastic syndrome
marrow toxicity consumption
Qinghuang Powder Capsule
hematology pro-gress
